Inhibiting Mer/Axl signaling or blocking α-synuclein TLR1/2 engagement may, therefore, attenuate maladaptive microglial training and offer neuroprotective benefit in PD (Hanke and Kielian, 2011). Here, TLR1 is linked to Parkinson disease.